Phuturdex › Diseases › Behavior
Drugs in development · updated 10 November 2026
Behavior: drugs in development
What it is
The observable response of a man or animal to a situation.
Source: NLM MeSH (U.S. National Library of Medicine), descriptor D001519, meshb.nlm.nih.gov · public domain · downloaded on 10 November 2026.
As of 10 November 2026 there are 283 active clinical trials (recruiting or ongoing, phases I–III) on 186 drugs for behavior. 65 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 10 November 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 65 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ketamineketamin, Ketalar® | II–III | 28 | NCT06891300 |
| NicotineNicotrol®, Nicoderm Cq® | II–III | 15 | NCT05413122 |
| VareniclineTyrvaya®, Chantix® | II–III | 10 | NCT05413122 |
| CannabidiolEpidiolex, Epidyolex | II–III | 7 | NCT07148843 |
| MidazolamMidazolam Hydrochloride (Autoinjector)®, Midazolam In 0.8% Sodium Chloride® | II–III | 7 | NCT07928947 |
| AlcoholEthanol, Dehydrated alcohol | II–III | 5 | NCT06065657 |
| SertralineZoloft® | II–III | 5 | NCT07574060 |
| BupropionForfivo Xl®, Aplenzin® | III | 4 | NCT07766655 |
| MethylphenidateConcerta, Relexxii® | II–III | 4 | NCT05474846 |
| SemaglutideWegovy, Rybelsus | III | 4 | NCT07021937 |
| DronabinolTetrahydrocannabinol, Delta-9-THC | II–III | 3 | NCT07422311 |
| EscitalopramLexapro | III | 3 | NCT03108846 |
| EsketamineSpravato | III | 3 | NCT06713616 |
| MemantineNamenda, Memantine Mylan® | II–III | 3 | NCT05796752 |
| CabotegravirAPRETUDE, Vocabria® | III | 2 | NCT06507059 |
Sorted by most advanced phase and number of active trials. Showing 15 of 121 drugs.
Sites in Europe
474 sites of the active trials in 26 European countries, 303 recruiting.
- Poland68
- United Kingdom62
- France52
- Spain49
- Germany41
- Czechia35
- Italy34
- Bulgaria22
- and 18 more
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
All 186 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Depression 72 drugs
- Major depressive disorder 66 drugs
- Anxiety disorder 54 drugs
- Smoking cessation 14 drugs
- Depressive Disorder, Treatment-Resistant 21 drugs
- Alcoholism 53 drugs
- Suicidal ideation 9 drugs
- Alcohol Drinking 11 drugs
- Smoking 18 drugs
- Post-traumatic stress disorder 39 drugs
- Depressive disorder 85 drugs
- Mood disorder 101 drugs
Broader categories
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 10 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001519 “Behavior”.